Blueprint gets green light on PhI studies; Eyegate inks Valeant deal; pSivida sees positive results in PhII eye study;

@FierceBiotech: Roche hustles to FDA with PhII PD-L1 cancer success for 'breakthrough' star atezolizumab. News | Follow @FierceBiotech

@JohnCFierce: You want to see why execs are leaving Big Pharma for biotech? It's where the money is. Report | Follow @JohnCFierce

@DamianFierce: Actual line: "Sorrento recently entered into a definitive agreement with NantPharma to acquire the rights for Cynviloq™ from Sorrento." | Follow @DamianFierce

> The FDA has OK'd two Phase I studies for Blueprint Medicines' two lead drugs. Release

> Waltham, MA-based EyeGate struck a licensing deal with Valeant giving the pharma company worldwide commercial and manufacturing rights to its EyeGate II Delivery System and EGP-437 combination product for uveitis. The deal comes with a private package of potential milestones and an upfront payment. Release

> Watertown, MA-based pSivida Corp. announced positive top line results from a Phase II study of pSivida's Medidur for uveitis affecting the posterior of the eye. Release

> Jersey City, NJ-based Aoxing Pharmaceuticals says that its sublingual tablets of Buprenorphine/Naloxone for opioid dependence delivered promising results in a study, setting the company on track to a filing with China's regulatory authorities. Release

Medical Device News

@FierceMedDev: ICYMI: Magic material: graphene protects chemotherapy, but silver-lined catheters break it down. Article | Follow @FierceMedDev

@StacyALawrence: Aum Cardio raises $5M to back hand-held, in-office CAD Dx device. Article | Follow @StacyALawrence

@EmilyWFierce: The experience of having your blood drawn by Theranos, as laid out by @danmunro. More | Follow @EmilyWFierce

> German prosthetics company mulls IPO for 2017. Story

> U.S. House passes provision to keep tabs on medical devices used on patients. Article

Pharma News

@FiercePharma: Did squirrels pass a killer virus to people? FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Which companies had highest comped CEOs? Hint, most are U.S. and did not necessarily make the most money. Special report | Follow @EricPFierce

@CarlyHFierce: I triple-dog-dare someone to make this new creepy-as-hell $GSK vaccine ad their Twitter pic. Story | Follow @CarlyHFierce

> Otsuka, Lundbeck bag blockbuster FDA approval for long-acting antipsychotic Rexulti. More

> European safety watchdog digs into HPV vaccines again. Article

Animal Health News

> FDA cracks down on Vegas firm selling unapproved kidney drug for dogs and cats. Article

> Perdue ditches all antibiotics for new chicken line, General Mills goes cage-free. Report

> Did squirrels pass a killer virus to people? More

> Senate committee, USDA, poultry producers meet to discuss deadly U.S. avian flu outbreak. Story

> Sweden's Oasmia regains rights to cancer drugs from Zoetis, files for $23M IPO. Article

Biotech IT News

> 21st Century Cures Act clears House with data sharing, standardization sections intact. Story

> Genomics vs YouTube: Which will have the greater computing requirements in 2025? More

> GSK working to build Apple's ResearchKit into its clinical trials. Report

> Financially motivated hackers break into 3 major pharma companies in 18 months. Article

> Core Informatics snags $17.5M to fuel lab software land grab. Story

Pharma Marketing News

> Novartis off to scorching start with Copaxone generic Glatopa. Article

> Novo Nordisk looks past blockbuster Victoza with PhIII success for weekly GLP-1 med. Item

> For Entresto rollout, Novartis marketing mixes tried-and-true with new-and-different. Story

> How does the Keytruda-Opdivo marketing battle stack up? More

> GSK's big, bad whooping cough vaccination campaign bares its teeth. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.